Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista JRG de Estudos Acadêmicos |
Texto Completo: | http://revistajrg.com/index.php/jrg/article/view/862 |
Resumo: | Acute lymphoblastic leukemia (ALL) is a type of cancer that affects blood and bone marrow cells. It is most common in children and young adults, representing the majority of childhood cancer cases. ALL can be treated with intensive chemotherapy, but this treatment can have significant adverse effects, especially in young patients. In recent years, CAR-T cell immunotherapy has emerged as a promising new approach for the treatment of ALL. CAR-T cells are immune cells modified in the laboratory to specifically attack cancer cells. Studies have shown complete remission rates of up to 90% in patients treated with CAR-T cells. However, this treatment can also have important side effects, such as cytokine release syndrome and neurotoxicity. Despite this, CAR-T cell therapy has shown promising results and may be an effective option for patients with refractory or relapsed ALL. Objective: To discuss ALL, emphasizing the effectiveness of immunotherapy with CAR-T cells as an innovative treatment. Methodology: An integrative literature review was carried out through publications indexed in the Scielo, Google Scholar, PubMed and Virtual Health Library (VHL) databases, using the descriptors: CAR-T, Acute Lymphoid Leukemia, Relapse in children and Immunotherapy in LLA. The use of CAR-T cell therapy to treat this disease has been considered a promising approach, with encouraging results in the feasibility and safety of its use, proving to be a powerful and highly selective tool, which allows specific focus in malignant cells. |
id |
JRG_8509e86c70cb5ce3607af5faf5fe92b8 |
---|---|
oai_identifier_str |
oai:ojs2.revistajrg.com:article/862 |
network_acronym_str |
JRG |
network_name_str |
Revista JRG de Estudos Acadêmicos |
repository_id_str |
|
spelling |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapyTecnologia promissora no combate à leucemia Linfoblástica aguda: explorando a eficácia da imunoterapia CAR-TImunoterapiaCélulas CAR-TLeucemia Linfoblástica AgudaAcute Lymphoblastic LeukemiaCar-T CellsImmunotherapyAcute lymphoblastic leukemia (ALL) is a type of cancer that affects blood and bone marrow cells. It is most common in children and young adults, representing the majority of childhood cancer cases. ALL can be treated with intensive chemotherapy, but this treatment can have significant adverse effects, especially in young patients. In recent years, CAR-T cell immunotherapy has emerged as a promising new approach for the treatment of ALL. CAR-T cells are immune cells modified in the laboratory to specifically attack cancer cells. Studies have shown complete remission rates of up to 90% in patients treated with CAR-T cells. However, this treatment can also have important side effects, such as cytokine release syndrome and neurotoxicity. Despite this, CAR-T cell therapy has shown promising results and may be an effective option for patients with refractory or relapsed ALL. Objective: To discuss ALL, emphasizing the effectiveness of immunotherapy with CAR-T cells as an innovative treatment. Methodology: An integrative literature review was carried out through publications indexed in the Scielo, Google Scholar, PubMed and Virtual Health Library (VHL) databases, using the descriptors: CAR-T, Acute Lymphoid Leukemia, Relapse in children and Immunotherapy in LLA. The use of CAR-T cell therapy to treat this disease has been considered a promising approach, with encouraging results in the feasibility and safety of its use, proving to be a powerful and highly selective tool, which allows specific focus in malignant cells.A leucemia linfóide aguda (LLA) é um tipo de câncer que afeta as células sanguíneas e da medula óssea. É mais comum em crianças e adultos jovens, representando a maior parte dos casos de câncer infantil. A LLA pode ser tratada com quimioterapia intensiva, mas esse tratamento pode ter efeitos adversos significativos, especialmente em pacientes jovens. Nos últimos anos, a imunoterapia com células CAR-T tem se destacado como uma nova abordagem promissora para o tratamento da LLA. As células CAR-T são células do sistema imunológico modificadas em laboratório para atacar especificamente as células cancerígenas. Estudos têm mostrado taxas de remissão completa de até 90% em pacientes tratados com células CAR-T. No entanto, esse tratamento também pode ter efeitos colaterais importantes, como a síndrome de liberação de citocinas e a neurotoxicidade. Apesar disso, a terapia com células CAR-T tem mostradoresultados promissores e pode ser uma opção eficaz para pacientes com LLA refratária ou recidivante. Objetivo: Discorrer sobre a LLA enfatizando a eficácia da imunoterapia com células CAR-T como tratamento inovador. Metodologia: Foi realizada uma revisão integrativa de literatura por meio de publicações indexada as bases de dados Scielo, Google Acadêmico, PubMed e Biblioteca Virtual em Saúde (BVS), utilizando os descritores: CAR-T, Leucemia Linfoide Aguda, Recidiva em crianças e Imunoterapia em LLA. A utilização da terapia com células CAR-T para o tratamento dessa enfermidade tem sido considerada uma abordagem promissora, com resultados animadores na viabilidade e na segurança do seu uso, mostrando-se uma ferramenta poderosa e de alta seletividade, o que permite o foco específico nas células malignas.Editora JRG2023-12-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigo avaliado pelos Paresapplication/pdfhttp://revistajrg.com/index.php/jrg/article/view/86210.55892/jrg.v6i13.862ark:/57118/JRG.v6i13.862JRG Journal of Academic Studies; Vol. 6 No. 13 (2023): JRG Journal of Academic Studies; 2524-2535JRG Journal of Academic Studies ; Vol. 6 Núm. 13 (2023): Revista JRG de Estudos Acadêmicos; 2524-2535JRG Journal of Academic Studies; V. 6 N. 13 (2023): Revista JRG de Estudos Acadêmicos; 2524-2535Revista JRG de Estudos Acadêmicos ; v. 6 n. 13 (2023): Revista JRG de Estudos Acadêmicos; 2524-25352595-1661ark:/57118/jrg.v6i13reponame:Revista JRG de Estudos Acadêmicosinstname:Editora JRGinstacron:JRGporhttp://revistajrg.com/index.php/jrg/article/view/862/785https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessPrass, Débora Tatiane ZamboniPorto, Emmylle SoaresSantos, Iranilde Silva dosDelgado Neto, Leoncio Rodrigues Pereira, Savyo Geovanne SilvaPerondi, Brenda Lúcia Burtuli2023-12-07T18:56:25Zoai:ojs2.revistajrg.com:article/862Revistahttp://revistajrg.com/index.php/jrgPRIhttp://revistajrg.com/index.php/jrg/oaiprofessorjonas@gmail.com||2595-16612595-1661opendoar:2023-12-07T18:56:25Revista JRG de Estudos Acadêmicos - Editora JRGfalse |
dc.title.none.fl_str_mv |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy Tecnologia promissora no combate à leucemia Linfoblástica aguda: explorando a eficácia da imunoterapia CAR-T |
title |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy |
spellingShingle |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy Prass, Débora Tatiane Zamboni Imunoterapia Células CAR-T Leucemia Linfoblástica Aguda Acute Lymphoblastic Leukemia Car-T Cells Immunotherapy |
title_short |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy |
title_full |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy |
title_fullStr |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy |
title_full_unstemmed |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy |
title_sort |
Promising technology to combat acute lymphoblastic leukemia: exploring the effectiveness of CAR-T immunotherapy |
author |
Prass, Débora Tatiane Zamboni |
author_facet |
Prass, Débora Tatiane Zamboni Porto, Emmylle Soares Santos, Iranilde Silva dos Delgado Neto, Leoncio Rodrigues Pereira, Savyo Geovanne Silva Perondi, Brenda Lúcia Burtuli |
author_role |
author |
author2 |
Porto, Emmylle Soares Santos, Iranilde Silva dos Delgado Neto, Leoncio Rodrigues Pereira, Savyo Geovanne Silva Perondi, Brenda Lúcia Burtuli |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Prass, Débora Tatiane Zamboni Porto, Emmylle Soares Santos, Iranilde Silva dos Delgado Neto, Leoncio Rodrigues Pereira, Savyo Geovanne Silva Perondi, Brenda Lúcia Burtuli |
dc.subject.por.fl_str_mv |
Imunoterapia Células CAR-T Leucemia Linfoblástica Aguda Acute Lymphoblastic Leukemia Car-T Cells Immunotherapy |
topic |
Imunoterapia Células CAR-T Leucemia Linfoblástica Aguda Acute Lymphoblastic Leukemia Car-T Cells Immunotherapy |
description |
Acute lymphoblastic leukemia (ALL) is a type of cancer that affects blood and bone marrow cells. It is most common in children and young adults, representing the majority of childhood cancer cases. ALL can be treated with intensive chemotherapy, but this treatment can have significant adverse effects, especially in young patients. In recent years, CAR-T cell immunotherapy has emerged as a promising new approach for the treatment of ALL. CAR-T cells are immune cells modified in the laboratory to specifically attack cancer cells. Studies have shown complete remission rates of up to 90% in patients treated with CAR-T cells. However, this treatment can also have important side effects, such as cytokine release syndrome and neurotoxicity. Despite this, CAR-T cell therapy has shown promising results and may be an effective option for patients with refractory or relapsed ALL. Objective: To discuss ALL, emphasizing the effectiveness of immunotherapy with CAR-T cells as an innovative treatment. Methodology: An integrative literature review was carried out through publications indexed in the Scielo, Google Scholar, PubMed and Virtual Health Library (VHL) databases, using the descriptors: CAR-T, Acute Lymphoid Leukemia, Relapse in children and Immunotherapy in LLA. The use of CAR-T cell therapy to treat this disease has been considered a promising approach, with encouraging results in the feasibility and safety of its use, proving to be a powerful and highly selective tool, which allows specific focus in malignant cells. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-12-11 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigo avaliado pelos Pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://revistajrg.com/index.php/jrg/article/view/862 10.55892/jrg.v6i13.862 ark:/57118/JRG.v6i13.862 |
url |
http://revistajrg.com/index.php/jrg/article/view/862 |
identifier_str_mv |
10.55892/jrg.v6i13.862 ark:/57118/JRG.v6i13.862 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://revistajrg.com/index.php/jrg/article/view/862/785 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Editora JRG |
publisher.none.fl_str_mv |
Editora JRG |
dc.source.none.fl_str_mv |
JRG Journal of Academic Studies; Vol. 6 No. 13 (2023): JRG Journal of Academic Studies; 2524-2535 JRG Journal of Academic Studies ; Vol. 6 Núm. 13 (2023): Revista JRG de Estudos Acadêmicos; 2524-2535 JRG Journal of Academic Studies; V. 6 N. 13 (2023): Revista JRG de Estudos Acadêmicos; 2524-2535 Revista JRG de Estudos Acadêmicos ; v. 6 n. 13 (2023): Revista JRG de Estudos Acadêmicos; 2524-2535 2595-1661 ark:/57118/jrg.v6i13 reponame:Revista JRG de Estudos Acadêmicos instname:Editora JRG instacron:JRG |
instname_str |
Editora JRG |
instacron_str |
JRG |
institution |
JRG |
reponame_str |
Revista JRG de Estudos Acadêmicos |
collection |
Revista JRG de Estudos Acadêmicos |
repository.name.fl_str_mv |
Revista JRG de Estudos Acadêmicos - Editora JRG |
repository.mail.fl_str_mv |
professorjonas@gmail.com|| |
_version_ |
1797068982785671168 |